United States December 2021 Paxlovid Pfizers Novel Covid Oral Antiviral — Fotografia de Stock
Apenas Uso Editorial

United States - december, 16, 2021: Paxlovid, Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study — Fotografia Editorial de Stock

United States - december, 16, 2021: Paxlovid, Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study

 — Fotografia por Giovanni_Cancemi

Mesma Série:

United States - december, 16, 2021: Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
United States December 2021 Pfizer Novel Covid Oral Antiviral Treatment — Fotografia de Stock
United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study
United States December 2021 Pfizers Novel Covid Oral Antiviral Treatment — Fotografia de Stock
United States - december, 16, 2021: Paxlovid, Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
United States December 2021 Paxlovid Pfizer Novel Covid Oral Antiviral — Fotografia de Stock
United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study
United States December 2021 Pfizers Novel Covid Oral Antiviral Treatment — Fotografia de Stock
United States - december, 16, 2021 Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study
United States December 2021 Pfizers Novel Covid Oral Antiviral Treatment — Fotografia de Stock
EE.UU.-17 de janeiro de 2022: Paxlovid, Pfizers comprimido oral COVID-19, aprovado no Canadá
Janeiro 2022 Paxlovid Pfizers Comprimido Oral Covid Aprovado Canadá — Fotografia de Stock
Taly - January, 03, 2022 Molnupiravir capsule antiviral drug pill for anti Coronavirus (COVID-19) developed by Merck and Co. 3D Rendering
Taly January 2022 Molnupiravir Capsule Antiviral Drug Pill Coronavirus Covid — Fotografia de Stock
Italy - January, 03, 2022: Molnupiravir capsule antiviral drug pill for anti Coronavirus(COVID-19) developed by Merck and Co. 3D Rendering
Italy January 2022 Molnupiravir Capsule Antiviral Drug Pill Coronavirus Covid — Fotografia de Stock
EE.UU. - 17 de janeiro de 2022: Paxlovid, Pfizers pílula oral COVID-19, aprovado no Canadá
Janeiro 2022 Paxlovid Pfizers Pílula Oral Covid Aprovado Canadá — Fotografia de Stock
Homem com pílula
Homem com pílula — Fotografia de Stock
Homem com pílula
Homem com pílula — Fotografia de Stock
Frasco de pílulas de dieta
Frasco de pílulas de dieta — Fotografia de Stock
A detecção de drogas na urina
A detecção de drogas na urina — Fotografia de Stock
Italy - January, 03, 2022: Molnupiravir capsule antiviral drug pill for anti Coronavirus (COVID-19) developed by Merck and Co. 3D Rendering
Italy January 2022 Molnupiravir Capsule Antiviral Drug Pill Coronavirus Covid — Fotografia de Stock
Homem com pílula na cabeça
Homem com pílula na cabeça — Fotografia de Stock
Exame de sangue de coronavírus em laboratório hospitalar
Exame de sangue de coronavírus em laboratório hospitalar — Fotografia de Stock

Informações de Utilização

Pode utilizar esta fotografia editorial sem royalties "United States - december, 16, 2021: Paxlovid, Pfizers Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 in Interim Analysis of Phase 23 EPIC-HR Study" para fins pessoais e não comerciais, de acordo com a Licença Padrão. Esta imagem de stock pode ser utilizada para ilustrar histórias em artigos de jornais, revistas e publicações em blogues. De notar que as fotografias editoriais de stock não podem ser utilizadas em publicidade ou material promocional.

Pode comprar esta fotografia editorial e descarregá-la em alta resolução até 5000x5000. Data do Carregamento: 28 de dez. de 2021